Form 4: SeaStar Medical CEO Awarded 30,000 RSUs

SeaStar Medical Holding Corp's CEO, Eric Schlorff, was granted 30,000 Restricted Stock Units (RSUs) vesting over three years.

Summary

• Eric Schlorff, Chief Executive Officer of SeaStar Medical Holding Corp (ICU), was granted 30,000 shares of Common Stock.
• The transaction occurred on February 6, 2026, and represents a Restricted Stock Unit (RSU) award.
• The RSUs were acquired at a price of $0, indicating they are part of compensation.
• Following this transaction, Eric Schlorff beneficially owns 39,852 shares of Common Stock.
• The RSU award vests in equal installments on the first, second, and third anniversaries of February 6, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting standard executive compensation practices designed to align management's interests with long-term shareholder value, without indicating any immediate operational changes or financial distress.

Positives

• The RSU award aligns the CEO's long-term interests with those of shareholders, as the value of the award is tied to the company's stock performance.
• Granting RSUs is a common practice for executive compensation, signaling confidence in future performance.

Negatives

• The award is a future event (February 6, 2026), so it does not reflect immediate value or a current cash investment by the CEO.
• RSUs dilute existing shareholder value upon vesting, though this is typically factored into compensation plans.

Future Outlook

The RSU award vesting over three years implies an expectation of continued employment and a long-term commitment from the CEO, aligning his incentives with the company's future performance through February 2029.

Industry Context

StockSavvy.ai notes that RSU awards are a standard component of executive compensation packages in the biotechnology and medical device industries, aiming to retain key talent and incentivize long-term value creation. This grant to SeaStar Medical's CEO is consistent with typical industry practices for aligning executive interests with shareholder returns.

Comparison to Industry Standards

• The grant of 30,000 RSUs to a CEO of a company like SeaStar Medical (a relatively small-cap medical device company) is within the typical range for executive compensation, comparable to grants seen at similar-stage biotech firms.
• For instance, CEOs at companies like Avinger, Inc. (AVGR) or Inspire Medical Systems (INSP) often receive RSU grants of similar magnitude, adjusted for market capitalization and performance metrics.
• The three-year vesting schedule is also standard, promoting long-term retention and performance.

Related Party Transactions

• The RSU award to the CEO could be considered a related party transaction, as it involves compensation to an executive.

Stakeholder Impact

• Shareholders: Potential long-term alignment of CEO interests with shareholder value; minor dilution upon vesting.
• Employees: May signal stability in leadership and a commitment to long-term strategy.
• Management: Provides a significant long-term incentive tied to company performance.

Next Steps

• The RSU award will vest in equal installments on February 6, 2027, February 6, 2028, and February 6, 2029.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (RSU grant) that aligns the CEO's interests with long-term shareholder value. It does not contain information that would fundamentally alter the company's financial outlook or operational performance in the short term, thus a 'hold' recommendation is appropriate as it maintains the current investment stance based on existing company fundamentals.

Keywords

SeaStar Medical Holding Corp, ICU, Eric Schlorff, Restricted Stock Units, RSU award, executive compensation, insider transaction, Form 4, beneficial ownership